| 0.7286 0.049 (7.15%) | 03-13 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 1.26 |
1-year : | 1.61 |
| Resists | First : | 1.08 |
Second : | 1.37 |
| Pivot price | 0.8 |
|||
| Supports | First : | 0.61 | Second : | 0.5 |
| MAs | MA(5) : | 0.7 |
MA(20) : | 0.89 |
| MA(100) : | 1.32 |
MA(250) : | 4.16 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 15.2 |
D(3) : | 14 |
| RSI | RSI(14): 39.4 |
|||
| 52-week | High : | 34.91 | Low : | 0.61 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ AIM ] has closed above bottom band by 37.7%. Bollinger Bands are 22% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.73 - 0.73 | 0.73 - 0.74 |
| Low: | 0.66 - 0.67 | 0.67 - 0.67 |
| Close: | 0.72 - 0.73 | 0.73 - 0.73 |
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. Its flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts. The company is also developing Ampligen for potential treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.
Tue, 10 Mar 2026
AIM ImmunoTech (AIM) director gets Series G preferred and 50,000 warrants - Stock Titan
Fri, 06 Mar 2026
AIM ImmunoTech (NYSE: AIM) raises $1.8M, issues Series G preferred and warrants - Stock Titan
Fri, 06 Mar 2026
Cancer-drug developer AIM ImmunoTech draws $1.8M in $1,000 rights sale - Stock Titan
Fri, 06 Mar 2026
AIM ImmunoTech Announces Closing of its Rights Offering - GlobeNewswire
Wed, 04 Mar 2026
AIM ImmunoTech raises $1.8M with $1,000 preferred stock and warrant bundles - Stock Titan
Fri, 27 Feb 2026
AIM ImmunoTech Reminds Stockholders of March 3, 2026 - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
AMEX
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|